Cutaneous Lupus Erythematosus- Pipeline Insight, 2024

Cutaneous Lupus Erythematosus- Pipeline Insight, 2024

DelveInsight’s, “ Cutaneous Lupus Erythematosus- Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cutaneous Lupus Erythematosus Understanding

Cutaneous Lupus Erythematosus: Overview

Cutaneous lupus Erythematosus (CLE) is an autoimmune skin disease that severely impairs quality of life. CLE may present as skin disease alone or may occur in the setting of systemic lupus Erythematosus (SLE), a severe multiorgan autoimmune disease with a wide variety of disease manifestations. In addition, patients initially diagnosed with isolated CLE may later progress to SLE. CLE is subdivided into acute, subacute, or chronic cutaneous lupus Erythematosus (ACLE, SCLE, or CCLE, respectively) based on lesion morphology and histopathology. CCLE accounts for approximately 80% of CLE, and discoid lupus Erythematosus (DLE) comprises the majority of CCLE. The CLE subsets not only have different morphology and histopathology, but also have different rates of association with SLE. ACLE is characterized by malar erythema (the classic “butterfly rash” of lupus) and/or widespread photodistributed erythema, and it is almost always found in association with SLE. In contrast, patients with localized DLE present with skin lesions limited to the head and neck that are characterized initially by erythema, induration, and scale, followed by the development of scarring, hypopigmentation, atrophy, and permanent alopecia. A subset of patients with DLE can develop more extensive or generalized lesions beyond the head and neck to involve the trunk and extremities. Patients initially diagnosed with DLE develop systemic involvement in 10-20% of cases, with some studies suggesting that patients with generalized lesions are at higher risk than those with localized DLE.

“Cutaneous Lupus Erythematosus- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cutaneous Lupus Erythematosus pipeline landscape is provided which includes the disease overview and Cutaneous Lupus Erythematosus treatment guidelines. The assessment part of the report embraces, in depth Cutaneous Lupus Erythematosus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cutaneous Lupus Erythematosus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous Lupus Erythematosus R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous Lupus Erythematosus.

Cutaneous Lupus Erythematosus Emerging Drugs Chapters

This segment of the Cutaneous Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cutaneous Lupus Erythematosus Emerging Drugs

• BIIB059: Biogen

BIIB059, discovered and developed exclusively by Biogen, is a fully humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) currently being investigated for the treatment of CLE and SLE. BDCA2 is a receptor that is uniquely expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs), and it has been shown to reduce inflammatory cytokine production from pDCs, including type-I IFN (IFN-I). Inflammatory mediators are thought to play a major role in the pathogenesis of lupus.

Further product details are provided in the report……..

Cutaneous Lupus Erythematosus: Therapeutic Assessment

This segment of the report provides insights about the different Cutaneous Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cutaneous Lupus Erythematosus

There are approx. 8+ key companies which are developing the therapies for Cutaneous Lupus Erythematosus. The companies which have their Cutaneous Lupus Erythematosus drug candidates in the most advanced stage, i.e. Phase II stage include, Biogen.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cutaneous Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cutaneous Lupus Erythematosus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus drugs.

Cutaneous Lupus Erythematosus Report Insights

• Cutaneous Lupus Erythematosus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cutaneous Lupus Erythematosus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cutaneous Lupus Erythematosus drugs?
• How many Cutaneous Lupus Erythematosus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous Lupus Erythematosus?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cutaneous Lupus Erythematosus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cutaneous Lupus Erythematosus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Hoth Therapeutics
• Centessa Pharmaceuticals
• Bristol-Myers Squibb
• Merck
• Biogen
• Sanofi
• Biogen

Key Products

• HT-005
• CBS004
• BMS-986256
• M5049
• BMS-986165 (deucravacitinib)
• BIIB059
• SAR443122